Similar to adults, children with TB require an intensive phase of treatment followed by a continuation phase to avoid emergence of resistant strains and achieve sterilization, respectively. But children have many unique considerations that must be addressed to provide effective treatment, including child-specific drug metabolism, distribution, and clearance. Unfortunately, drug recommendations for children have been largely based on adult studies. Similarly, child-friendly drug formulations are absent in many settings as drug preparation largely focuses on therapy for adults. Our research team is collaborating with colleagues, including the IMPAACT consortium, to better understand the pediatric-specific TB pharmacokinetics and identify short and effective treatment regimens.